https://youtu.be/Ih7dZBAV-uk?si=VWYOr4wXM04KgQYA.

Supriya life 39 years old company,Complete backward integration, 87% from export supply in 86 countries, CDMO CMO not generate any revenue at this point, shifted from China to Europe, one product dependency on China is now lesser , china cfda also visit the our GMP certified plant with minimal observation, expanding our anaesthetic portfolio, 300 million dollar global opportunity size with 4-5% of CAGR, 28-30% EBITDA,120-150 cr profit & 100 cr capex all capex funded by internal approvals, 20% growth, 1000 cr sales targets fy27, DSM fair ( Europe) get 10 year contract of vitamin sole supplier , globally contact mfg from next 2-3 years expected 60 cr revenue per years, inventory day is below 150 days is our Target, pls watch video also..

Disc invested recently added, no reco

So this 150 day Lockin is guideline by SEBI or Indigo had some arrangements with RS Gangwal Group

Zenith was allotted bonus as well as converted equity shares as per the company release on Feb 28. Converted shares were allotted upon payment to JTL.

Technically JTL would have nothing to do with Zenith’s shares being frozen. But I feel that the street is having concern whether management is involved in any way or not.

Zenith holding seems <1% so not very concerning…but I think management should issue some clarification which would help the street.

Valuation-wise the stock is a buy but this event is an overhang coupled with a bearish market trend.

The Company has received Rs 2,11,61,000/- (Rupees Two Crores Eleven Lakhs and Sixty-One Thousand only) as incentives for the fiscal year 2022-23 under the PLI (Production – Linked Incentive) Scheme for Telecom and Networking Products and the said amount accounts for 100% of the total claim for the FY 2022-23.
FROG_11032024162512_Disclosure_PLI.pdf (617.8 KB)